Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock

NEXT STORY
XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis
PREV STORY
Celldex Therapeutics Announces Upcoming Data Presentations
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent

HOUSTON, July 19, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company ...

author_avatar
NASDAQ Market News

Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

author_avatar
NASDAQ Market News

Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

author_avatar
NASDAQ Market News